Cover Image
市場調查報告書

旅人腹瀉症:開發中產品分析

Traveler's Diarrhea - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 257795
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
旅人腹瀉症:開發中產品分析 Traveler's Diarrhea - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 54 Pages
簡介

旅人腹瀉症是胃及腸的感染疾病,是由於攝取處理過程不衛生的食物引起的。常見的症狀有腹部痙攣、噁心、嘔吐、發燒等症狀。致病因子有年齡、免疫系統低落、糖尿病或是發炎性腸道疾病、制酸劑等。治療方法包含有抑制腸道動藥及抗生素等。

本報告提供旅人腹瀉症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

旅人腹瀉症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

研究中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

研究中的產品:各大學/研究機關

開發治療藥的企業

  • Cosmo Pharmaceuticals NV
  • GlaxoSmithKline Plc
  • 日本新藥
  • Prokarium Limited
  • Scandinavian Biopharma Holding AB
  • Sigmoid Pharma Limited

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發暫停中的產品

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8427IDB

Summary

Global Markets Direct's, 'Traveler's Diarrhea - Pipeline Review, H2 2016', provides an overview of the Traveler's Diarrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Traveler's Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traveler's Diarrhea and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Traveler's Diarrhea
  • The report reviews pipeline therapeutics for Traveler's Diarrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Traveler's Diarrhea therapeutics and enlists all their major and minor projects
  • The report assesses Traveler's Diarrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Traveler's Diarrhea

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Traveler's Diarrhea
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Traveler's Diarrhea pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Traveler's Diarrhea Overview
  • Therapeutics Development
    • Pipeline Products for Traveler's Diarrhea - Overview
    • Pipeline Products for Traveler's Diarrhea - Comparative Analysis
  • Traveler's Diarrhea - Therapeutics under Development by Companies
  • Traveler's Diarrhea - Therapeutics under Investigation by Universities/Institutes
  • Traveler's Diarrhea - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Traveler's Diarrhea - Products under Development by Companies
  • Traveler's Diarrhea - Products under Investigation by Universities/Institutes
  • Traveler's Diarrhea - Companies Involved in Therapeutics Development
    • Cosmo Pharmaceuticals NV
    • GlaxoSmithKline Plc
    • Nippon Shinyaku Co., Ltd.
    • Prokarium Limited
    • Scandinavian Biopharma Holding AB
    • Sigmoid Pharma Limited
  • Traveler's Diarrhea - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Etvax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GVXNSD-133 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMSUTMR-1501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • prulifloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rifamycin CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Typhetec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Traveler's Diarrhea - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Traveler's Diarrhea - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Traveler's Diarrhea - Dormant Projects
  • Traveler's Diarrhea - Discontinued Products
  • Traveler's Diarrhea - Product Development Milestones
    • Featured News & Press Releases
      • Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX
      • Oct 04, 2013: Santarus Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers' Diarrhea
      • Sep 11, 2012: Santarus Announces Positive Top-Line Phase III Results For Rifamycin SV MMX In Travelers' Diarrhea
      • Sep 14, 2009: Data From Optimers Second Phase III Study of Prulifloxacin Presented At Annual Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC)
      • Sep 02, 2009: Optimer Pharmaceuticals Announces Presentations Of Additional Phase III Prulifloxacin Data At Upcoming ICAAC Annual Meeting
      • Feb 26, 2009: Optimer Pharmaceuticals Announces Publication In Peer-Reviewed Journal About Prulifloxacins Antibacterial Activity Against Infectious Diarrhea Producing Bacteria
      • Feb 24, 2009: Optimer Pharmaceuticals Announces Positive Results From Second Phase III Study Of Prulifloxacin For Infectious Diarrhea In Travelers
      • Oct 20, 2008: Data from Optimer Pharmaceuticals Prulifloxacin Phase III Trial In Travelers Diarrhea Presented At ICAAC/IDSA Annual Meeting
      • Sep 02, 2008: Optimer Pharmaceuticals Completes Enrollment In Second Prulifloxacin Phase III Clinical Trial
      • Jul 16, 2008: Optimer Pharmaceuticals Announces Positive Results In Prulifloxacin Phase III Study
      • Mar 11, 2008: Optimer Pharmaceuticals Completes Enrollment In Phase III Clinical Trial Of Prulifloxacin In Patients with Travelers' Diarrhea
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Traveler's Diarrhea, H2 2016
  • Number of Products under Development for Traveler's Diarrhea - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Traveler's Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H2 2016
  • Traveler's Diarrhea - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Traveler's Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
  • Traveler's Diarrhea - Pipeline by Prokarium Limited, H2 2016
  • Traveler's Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2016
  • Traveler's Diarrhea - Pipeline by Sigmoid Pharma Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Traveler's Diarrhea - Dormant Projects, H2 2016
  • Traveler's Diarrhea - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Traveler's Diarrhea, H2 2016
  • Number of Products under Development for Traveler's Diarrhea - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top